{"id":142516,"date":"2026-07-07T16:16:06","date_gmt":"2026-07-07T10:46:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=142516"},"modified":"2026-07-07T16:16:07","modified_gmt":"2026-07-07T10:46:07","slug":"mankind-pharma-share-price-target-incred-add-2812","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/","title":{"rendered":"Mankind Pharma Share Price Target Set at Rs 2,812 as InCred Initiates Add Rating"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Mankind Pharma share price target Rs 2,812 as InCred initiates add rating. Cites shift toward R&amp;D and specialty therapies, BSV acquisition strengthening biologics. Stock down 0.76% at Rs 2,521.<\/em><\/p>\n<p>The <strong>Mankind Pharma share price target<\/strong> has been set at Rs 2,812 by InCred, which initiated coverage with an add rating on 7 July 2026. <a href=\"https:\/\/univest.in\/stocks\/mankind\/mankind-pharma-ltd-share-price-today\">Mankind Pharma<\/a> was quoting at Rs 2,521.00, down 0.76 percent, after touching an intraday high of Rs 2,579.15 and a low of Rs 2,521.00.<\/p>\n<p>InCred&#8217;s initiation cites a structural shift underway at Mankind Pharma, moving from a generics-led business model toward research and development along with specialty therapies, a transition the brokerage views as strategically significant even though it will take time to show up fully in earnings.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=mankind-pharma-share-price-target-incred-2812\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#InCreds_Mankind_Pharma_Share_Price_Target_Note_Key_Points\" title=\"InCred&#8217;s Mankind Pharma Share Price Target Note: Key Points\">InCred&#8217;s Mankind Pharma Share Price Target Note: Key Points<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#Why_InCred_Set_This_Mankind_Pharma_Share_Price_Target\" title=\"Why InCred Set This Mankind Pharma Share Price Target\">Why InCred Set This Mankind Pharma Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#What_the_Generics-to-Specialty_Shift_Means_for_Mankind_Pharma\" title=\"What the Generics-to-Specialty Shift Means for Mankind Pharma\">What the Generics-to-Specialty Shift Means for Mankind Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#What_Should_Investors_Watch_Next\" title=\"What Should Investors Watch Next\">What Should Investors Watch Next<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#Frequently_Asked_Questions_on_the_Mankind_Pharma_Share_Price_Target\" title=\"Frequently Asked Questions on the Mankind Pharma Share Price Target\">Frequently Asked Questions on the Mankind Pharma Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#What_is_InCreds_Mankind_Pharma_share_price_target\" title=\"What is InCred&#8217;s Mankind Pharma share price target?\">What is InCred&#8217;s Mankind Pharma share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#Why_did_InCred_initiate_coverage_on_Mankind_Pharma_with_an_add_rating\" title=\"Why did InCred initiate coverage on Mankind Pharma with an add rating?\">Why did InCred initiate coverage on Mankind Pharma with an add rating?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#Is_Mankind_Pharmas_recent_growth_organic_or_acquisition-driven\" title=\"Is Mankind Pharma&#8217;s recent growth organic or acquisition-driven?\">Is Mankind Pharma&#8217;s recent growth organic or acquisition-driven?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#What_is_the_Mankind_Pharma_share_price_today\" title=\"What is the Mankind Pharma share price today?\">What is the Mankind Pharma share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#What_is_the_BSV_acquisition_mentioned_in_InCreds_note\" title=\"What is the BSV acquisition mentioned in InCred&#8217;s note?\">What is the BSV acquisition mentioned in InCred&#8217;s note?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#Why_is_a_shift_from_generics_to_specialty_therapies_significant_for_pharma_companies\" title=\"Why is a shift from generics to specialty therapies significant for pharma companies?\">Why is a shift from generics to specialty therapies significant for pharma companies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-share-price-target-incred-add-2812\/#Should_investors_buy_Mankind_Pharma_based_on_InCreds_rating\" title=\"Should investors buy Mankind Pharma based on InCred&#8217;s rating?\">Should investors buy Mankind Pharma based on InCred&#8217;s rating?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"InCreds_Mankind_Pharma_Share_Price_Target_Note_Key_Points\"><\/span><strong>InCred&#8217;s Mankind Pharma Share Price Target Note: Key Points<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr>\n<th style=\"background: #1F3864; color: #ffffff; padding: 8px 12px; text-align: left; border: 1px solid #DDDDDD;\">Observation<\/th>\n<th style=\"background: #1F3864; color: #ffffff; padding: 8px 12px; text-align: left; border: 1px solid #DDDDDD;\">Detail<\/th>\n<\/tr>\n<tr>\n<td style=\"background: #F9F9F9; padding: 8px 12px; border: 1px solid #DDDDDD;\">Rating<\/td>\n<td style=\"background: #F9F9F9; padding: 8px 12px; border: 1px solid #DDDDDD;\">Add (initiated)<\/td>\n<\/tr>\n<tr>\n<td style=\"background: #FFFFFF; padding: 8px 12px; border: 1px solid #DDDDDD;\">Mankind Pharma Share Price Target<\/td>\n<td style=\"background: #FFFFFF; padding: 8px 12px; border: 1px solid #DDDDDD;\">Rs 2,812<\/td>\n<\/tr>\n<tr>\n<td style=\"background: #F9F9F9; padding: 8px 12px; border: 1px solid #DDDDDD;\">Implied Upside vs CMP (Rs 2,521)<\/td>\n<td style=\"background: #F9F9F9; padding: 8px 12px; border: 1px solid #DDDDDD;\">~11.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"background: #FFFFFF; padding: 8px 12px; border: 1px solid #DDDDDD;\">Strategic Shift Noted<\/td>\n<td style=\"background: #FFFFFF; padding: 8px 12px; border: 1px solid #DDDDDD;\">Generics-led model moving toward R&amp;D and specialty therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"background: #F9F9F9; padding: 8px 12px; border: 1px solid #DDDDDD;\">Key Deal Cited<\/td>\n<td style=\"background: #F9F9F9; padding: 8px 12px; border: 1px solid #DDDDDD;\">BSV acquisition strengthens specialty biologics portfolio<\/td>\n<\/tr>\n<tr>\n<td style=\"background: #FFFFFF; padding: 8px 12px; border: 1px solid #DDDDDD;\">Recent Growth Driver<\/td>\n<td style=\"background: #FFFFFF; padding: 8px 12px; border: 1px solid #DDDDDD;\">Acquisitions rather than organic volumes<\/td>\n<\/tr>\n<tr>\n<td style=\"background: #F9F9F9; padding: 8px 12px; border: 1px solid #DDDDDD;\">Outlook on Specialty Strategy<\/td>\n<td style=\"background: #F9F9F9; padding: 8px 12px; border: 1px solid #DDDDDD;\">Benefits expected to accrue gradually<\/td>\n<\/tr>\n<tr>\n<td style=\"background: #FFFFFF; padding: 8px 12px; border: 1px solid #DDDDDD;\">CMP (7 July 2026)<\/td>\n<td style=\"background: #FFFFFF; padding: 8px 12px; border: 1px solid #DDDDDD;\">Rs 2,521.00 (-0.76%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_InCred_Set_This_Mankind_Pharma_Share_Price_Target\"><\/span><strong>Why InCred Set This Mankind Pharma Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>InCred&#8217;s Rs 2,812 target reflects a constructive but measured view. The brokerage explicitly notes that Mankind Pharma&#8217;s recent growth has been driven more by acquisitions than organic volume expansion, with the BSV acquisition specifically called out as strengthening the company&#8217;s specialty biologics portfolio. This is a meaningful strategic pivot for a company historically known for its generics and consumer healthcare brands in the Indian market.<\/p>\n<p>Importantly, InCred frames the benefits from this specialty strategy as an outcome that will accrue gradually rather than immediately, tempering near-term earnings expectations even while the initiation itself carries a constructive add rating.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Get Research-Backed Stock Ideas from a SEBI Registered Investment Advisor<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_the_Generics-to-Specialty_Shift_Means_for_Mankind_Pharma\"><\/span><strong>What the Generics-to-Specialty Shift Means for Mankind Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>India&#8217;s pharmaceutical majors have increasingly looked to R&amp;D-driven specialty therapies and biologics to escape the margin pressure typical of commoditised generics manufacturing. Mankind Pharma&#8217;s pivot, anchored by the BSV acquisition, positions the company to participate in this broader industry shift, though InCred&#8217;s own note acknowledges that near-term growth is still acquisition-led rather than reflecting organic specialty pipeline traction yet.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Watch_Next\"><\/span><strong>What Should Investors Watch Next<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors tracking this Mankind Pharma share price target should watch for organic volume growth trends in the specialty and biologics segments in upcoming quarterly results, integration progress on the BSV acquisition, and whether other brokerages initiate or revise coverage with similar or differing views on the pace of this strategic transition.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Mankind Pharma live and get brokerage target updates daily.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>InCred has initiated an add rating on Mankind Pharma with a share price target of Rs 2,812, citing the company&#8217;s shift from a generics-led model toward R&amp;D and specialty therapies, anchored by the BSV acquisition. The stock traded at Rs 2,521.00 on 7 July 2026, down 0.76 percent. Organic growth in the specialty portfolio over coming quarters is the key thing to watch.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_the_Mankind_Pharma_Share_Price_Target\"><\/span><strong>Frequently Asked Questions on the Mankind Pharma Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_InCreds_Mankind_Pharma_share_price_target\"><\/span><strong>What is InCred&#8217;s Mankind Pharma share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> InCred has initiated an add rating on Mankind Pharma with a share price target of Rs 2,812, implying upside of about 11.5 percent from the stock&#8217;s current level of around Rs 2,521.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_InCred_initiate_coverage_on_Mankind_Pharma_with_an_add_rating\"><\/span><strong>Why did InCred initiate coverage on Mankind Pharma with an add rating?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> InCred&#8217;s initiation cites Mankind Pharma&#8217;s structural shift from a generics-led model toward R&amp;D and specialty therapies, with the BSV acquisition strengthening its specialty biologics portfolio.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Mankind_Pharmas_recent_growth_organic_or_acquisition-driven\"><\/span><strong>Is Mankind Pharma&#8217;s recent growth organic or acquisition-driven?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> According to InCred&#8217;s note, Mankind Pharma&#8217;s recent growth has been driven more by acquisitions than organic volumes, though the brokerage expects benefits from the specialty strategy to accrue gradually over time.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Mankind_Pharma_share_price_today\"><\/span><strong>What is the Mankind Pharma share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Mankind Pharma was quoting at Rs 2,521.00 on 7 July 2026, down 0.76 percent, after touching an intraday high of Rs 2,579.15 and a low of Rs 2,521.00.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_BSV_acquisition_mentioned_in_InCreds_note\"><\/span><strong>What is the BSV acquisition mentioned in InCred&#8217;s note?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The BSV acquisition is a deal that InCred cites as strengthening Mankind Pharma&#8217;s specialty biologics portfolio, forming a key part of the company&#8217;s strategic shift away from a purely generics-led business.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_a_shift_from_generics_to_specialty_therapies_significant_for_pharma_companies\"><\/span><strong>Why is a shift from generics to specialty therapies significant for pharma companies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Specialty therapies and biologics typically offer better margins and differentiation than commoditised generics, and Indian pharma majors have increasingly pursued this shift to escape pricing pressure in the generics business.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_investors_buy_Mankind_Pharma_based_on_InCreds_rating\"><\/span><strong>Should investors buy Mankind Pharma based on InCred&#8217;s rating?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not constitute investment advice. Investors should evaluate the pace of organic growth in the specialty portfolio and overall valuations, and consult a SEBI registered financial advisor before investing.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is InCred's Mankind Pharma share price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"InCred has initiated an add rating on Mankind Pharma with a share price target of Rs 2,812, implying upside of about 11.5 percent from the stock's current level of around Rs 2,521.\"}},{\"@type\":\"Question\",\"name\":\"Why did InCred initiate coverage on Mankind Pharma with an add rating?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"InCred's initiation cites Mankind Pharma's structural shift from a generics-led model toward R&D and specialty therapies, with the BSV acquisition strengthening its specialty biologics portfolio.\"}},{\"@type\":\"Question\",\"name\":\"Is Mankind Pharma's recent growth organic or acquisition-driven?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"According to InCred's note, Mankind Pharma's recent growth has been driven more by acquisitions than organic volumes, though the brokerage expects benefits from the specialty strategy to accrue gradually over time.\"}},{\"@type\":\"Question\",\"name\":\"What is the Mankind Pharma share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Mankind Pharma was quoting at Rs 2,521.00 on 7 July 2026, down 0.76 percent, after touching an intraday high of Rs 2,579.15 and a low of Rs 2,521.00.\"}},{\"@type\":\"Question\",\"name\":\"What is the BSV acquisition mentioned in InCred's note?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The BSV acquisition is a deal that InCred cites as strengthening Mankind Pharma's specialty biologics portfolio, forming a key part of the company's strategic shift away from a purely generics-led business.\"}},{\"@type\":\"Question\",\"name\":\"Why is a shift from generics to specialty therapies significant for pharma companies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Specialty therapies and biologics typically offer better margins and differentiation than commoditised generics, and Indian pharma majors have increasingly pursued this shift to escape pricing pressure in the generics business.\"}},{\"@type\":\"Question\",\"name\":\"Should investors buy Mankind Pharma based on InCred's rating?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not constitute investment advice. Investors should evaluate the pace of organic growth in the specialty portfolio and overall valuations, and consult a SEBI registered financial advisor before investing.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>InCred initiates add rating on Mankind Pharma with a share price target of Rs 2,812, citing a shift from generics toward R&#038;D and specialty therapies via the BSV acquisition. Full note on Univest.<\/p>\n","protected":false},"author":34,"featured_media":142580,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3972],"class_list":["post-142516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-share-price-target"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1783421171:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Mankind Pharma Share Price Target: InCred Add Rs 2,812"],"rank_math_description":["Mankind Pharma share price target of Rs 2,812 set by InCred as it initiates an add rating, citing the company's shift from generics toward R&amp;D and specialty therapies. Details here."],"rank_math_focus_keyword":["Mankind Pharma share price target"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["142580"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["24102"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Mankind-Pharma-Share-Price-Target.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/142516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=142516"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/142516\/revisions"}],"predecessor-version":[{"id":142581,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/142516\/revisions\/142581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/142580"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=142516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=142516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=142516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}